Broad HLA Portfolio HLA Protein Technologies offers a broad portfolio of soluble, natively folded HLA proteins across Class I and II with off the shelf availability and custom peptide validation plus T cell epitope mapping services. This breadth and the option for bespoke validation create upsell opportunities for labs needing specific alleles or tailored reagents from a single supplier.

Product Line Expansion The company recently launched a soluble HLA-G product portfolio, signaling momentum in product expansion. This presents an entry point to target researchers studying immune modulation and tolerance, as well as potential collaborations with pharma and CROs seeking to incorporate HLA-G reagents into their assays.

Quality Advantage Soluble reagents that are natively folded improve binding fidelity and reduce nonspecific interactions, enabling more accurate immune characterization. Position these high quality, standardized reagents to premium laboratories needing reliable T cell and B cell assay results.

Ideal Partners Small team with modest revenue indicates potential for scalable partnerships with larger biotechnology firms. Focus on mid to large immunology labs, pharmaceutical companies, and CROs for distribution, co development, or volume programs, using a short technical call to discuss custom projects.

Market Positioning Expanded allele coverage across Class I and II and the ability to map T cell epitopes position HLA Protein Technologies as a one stop source for diverse HLA reagents, enabling cross selling into labs needing broad allele panels and compatibility with immune assays.